Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virginia Devonshire

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
The Lancet. Neurology|April 13, 2012
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS studyVirginia Devonshire, Eva Havrdova, Ernst Wilhelm Radue, et al.
Frontiers in Neurology|June 7, 2022
Models of Care in Multiple Sclerosis: A Survey of Canadian Health ProvidersRuth Ann Marrie, Sarah J Donkers, Draga Jichici, et al.
Frontiers in Neurology|March 20, 2023
Good multiple sclerosis (MS) care and how to get there in Canada: Perspectives of Canadian healthcare providers working with persons with MSJulie Petrin, Ruth Ann Marrie, Virginia Devonshire, et al.
Neurology|December 6, 2012
MS, MRI, and the 2010 McDonald criteria: a Canadian expert commentaryDaniel Selchen, Virender Bhan, Gregg Blevins, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|July 14, 2020
Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group RecommendationsMark S Freedman, Virginia Devonshire, Pierre Duquette, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|June 9, 2025
First-Line Use of Higher-Efficacy Disease-Modifying Therapies in Multiple Sclerosis: Canadian Consensus RecommendationsMark S Freedman, Fraser Clift, Virginia Devonshire, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|February 12, 2020
Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis PatientsJillian K Chan, Elena Hernandez Martínez de Lapiscina, Carolyn Taylor, et al.
Frontiers in Neurology|January 29, 2021
Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian CohortHelen Cross, Farahna Sabiq, Nathalie Ackermans, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2021
Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imagingIrene M Vavasour, Peng Sun, Carina Graf, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 3, 2026
Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, CanadaNathan Y Chu, Jodie I Roberts, David J Hunt, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
The Lancet. Neurology|April 13, 2012
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS studyVirginia Devonshire, Eva Havrdova, Ernst Wilhelm Radue, et al.
Frontiers in Neurology|June 7, 2022
Models of Care in Multiple Sclerosis: A Survey of Canadian Health ProvidersRuth Ann Marrie, Sarah J Donkers, Draga Jichici, et al.
Frontiers in Neurology|March 20, 2023
Good multiple sclerosis (MS) care and how to get there in Canada: Perspectives of Canadian healthcare providers working with persons with MSJulie Petrin, Ruth Ann Marrie, Virginia Devonshire, et al.
Neurology|December 6, 2012
MS, MRI, and the 2010 McDonald criteria: a Canadian expert commentaryDaniel Selchen, Virender Bhan, Gregg Blevins, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|July 14, 2020
Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group RecommendationsMark S Freedman, Virginia Devonshire, Pierre Duquette, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|June 9, 2025
First-Line Use of Higher-Efficacy Disease-Modifying Therapies in Multiple Sclerosis: Canadian Consensus RecommendationsMark S Freedman, Fraser Clift, Virginia Devonshire, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|February 12, 2020
Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis PatientsJillian K Chan, Elena Hernandez Martínez de Lapiscina, Carolyn Taylor, et al.
Frontiers in Neurology|January 29, 2021
Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian CohortHelen Cross, Farahna Sabiq, Nathalie Ackermans, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 16, 2021
Characterization of multiple sclerosis neuroinflammation and neurodegeneration with relaxation and diffusion basis spectrum imagingIrene M Vavasour, Peng Sun, Carina Graf, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 3, 2026
Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, CanadaNathan Y Chu, Jodie I Roberts, David J Hunt, et al.
Pageof 4